PrintContact
 
  • Home
  • About Us
  • Sativex
  • R&D
  • Investors
  • Media
GW Pharmaceuticals

Meeting patients' needs...

Our vision

...is to be the global leader in prescription cannabinoid medicines, through the rapid cost-effective development of pharmaceutical products which address clear unmet patient needs.

 
PATIENTS

Therapeutic areas of focus, clinical trials and other information on Sativex...

Click here

 
MEDICAL PROFESSIONALS

Prescriber information, clinical publications and other information on Sativex...

Click here

 
MEDIA

Press releases, frequently asked questions and contact information for media enquiries...

Click here

 
INVESTORS

Share price, regulatory news, company presentations and other investor information..

Click here

 
 

Latest News

25 November 2009

Sativex® Phase II/III Cancer Pain Study Completes Patient Recruitment

25 November 2009

Preliminary Results for the Year Ended 30 September 2009

News archive

Sportlight

Spotlight image

Preliminary Results 2009

download the presentationClick here to listen to the webcast or download the presentation.

 

SHARE PRICE

GBp 93.12

1.00p 27/11/200916:12 GMT

 
 
 

© GW Pharmaceuticals 2009

  • Home
  • Sitemap
  • Accessibility
  • Disclosure & Disclaimer
  • Contact
  • Email Alerts
 

Website designed and developed by www.emperordesign.co.uk